Press Releases

NEW YORK , Feb. 21, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez , SIGA’s Chief Executive Officer, will present at the 8 th Annual SVB Leerink

NEW YORK , Nov. 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an agreement to sell its medical countermeasures priority review voucher (PRV) for

NEW YORK , Oct. 04, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States

- Company Hosting Business Update Webcast Today at 4:30pm ET - NEW YORK , Sept. 27, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L.

NEW YORK , Sept. 17, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M.

NEW YORK , Sept. 13, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company focused on the health security market, today announced that that management will be ringing the Nasdaq Stock Market Opening Bell on Friday, September 14, 2018 .

- Contract Valued at Up to $629 Million – - Contract Includes Delivery of Oral and Intravenous (IV) Formulations of TPOXX; Development of IV TPOXX; Post-marketing Activities – NEW YORK , Sept. 10, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ: SIGA ), a commercial-stage

- First therapy specifically approved for smallpox advances health security against a significant bioterror threat- - Company Granted Priority Review Voucher - NEW YORK , July 13, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ:SIGA), a commercial-stage pharmaceutical company

- Results support the use of TPOXX to treat smallpox, a highly contagious and lethal virus that poses significant bioterror threat - NEW YORK , July 05, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. ( SIGA ) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security

NEW YORK , May 31, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies , Inc. ( SIGA ) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez , SIGA’s Chief Executive Officer, will present at the Jefferies Global Healthcare